96 related articles for article (PubMed ID: 35792023)
1. Assessment of thyroiditis risk associated with HPV vaccination among girls aged 9-18 years: A time-varying cohort study.
Castillo-Cano B; Martín-Pérez M; Llorente-García A; Montero-Corominas D; Comas-Cufí M; Martín-Merino E
Vaccine; 2022 Aug; 40(33):4816-4826. PubMed ID: 35792023
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Risk of Inflammatory Bowel Disease after the HPV Vaccination in Primary Care in Spain: A Time-Varying Cohort Analysis of Around 390,000 Girls.
Martín-Merino E; Castillo-Cano B; Martín-Pérez M; Llorente-García A; Montero-Corominas D
Drug Saf; 2021 Apr; 44(4):455-466. PubMed ID: 33462777
[TBL] [Abstract][Full Text] [Related]
3. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.
Martín-Merino E; Llorente-García A; Castillo Cano B; Montero Corominas D; Huerta-Álvarez C
Pharmaceut Med; 2019 Dec; 33(6):519-530. PubMed ID: 31933243
[TBL] [Abstract][Full Text] [Related]
4. Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain.
Martín-Merino E; Castillo-Cano B; Martín-Perez M; Llorente-García A; Montero-Corominas D
Vaccine; 2021 Jul; 39(31):4306-4313. PubMed ID: 34175126
[TBL] [Abstract][Full Text] [Related]
5. The recording of human papillomavirus (HPV) vaccination in BIFAP primary care database: A validation study.
Martín-Merino E; Llorente-García A; Montero-Corominas D; Huerta C
Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):201-208. PubMed ID: 30488510
[TBL] [Abstract][Full Text] [Related]
6. Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study.
Yoon D; Lee JH; Lee H; Shin JY
BMJ; 2021 Jan; 372():m4931. PubMed ID: 33514507
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M
Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853
[TBL] [Abstract][Full Text] [Related]
8. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus vaccines and Guillain-Barré syndrome: managing uncertainties.
Prescrire Int; 2016 Nov; 25(176):265-268. PubMed ID: 30715823
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
11. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
12. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland.
Skufca J; Ollgren J; Artama M; Ruokokoski E; Nohynek H; Palmu AA
Vaccine; 2018 Sep; 36(39):5926-5933. PubMed ID: 30115524
[TBL] [Abstract][Full Text] [Related]
13. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
14. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
15. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
[TBL] [Abstract][Full Text] [Related]
16. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the risk of autoimmune thyroiditis, Guillain-Barré syndrome, and inflammatory bowel disease following vaccination with AS04-adjuvanted human papillomavirus 16/18 vaccine.
Rosillon D; Willame C; Tavares Da Silva F; Guignard A; Caterina S; Welby S; Struyf F
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1159-1167. PubMed ID: 32583515
[TBL] [Abstract][Full Text] [Related]
18. Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study.
Liu EY; Smith LM; Ellis AK; Whitaker H; Law B; Kwong JC; Farrington P; Lévesque LE
CMAJ; 2018 May; 190(21):E648-E655. PubMed ID: 29807937
[TBL] [Abstract][Full Text] [Related]
19. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
20. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
